Related Experiment Video
Updated: Sep 2, 2026

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
The structural MRI markers and cognitive decline in prodromal Alzheimer's disease: a 2-year longitudinal study
Hongchun Wei1, Min Kong2, Chunhua Zhang1
1Department of Neurology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai 264000, China.
Background:
Being clinically diagnosed with a mild cognitive impairment (MCI) due to Alzheimer's disease (AD) is widely studied. Yet, the clinical and structural neuroimaging characteristics for prodromal AD, which are defined as A+T+MCI based on the AT (N) system are still highly desirable. This study evaluates the differences of the cognitive assessments and structural magnetic resonance imaging (MRI) between the early MCI (EMCI) and late MCI (LMCI) participants based on the AT (N) system. The potential clinical value of the structural MRI as a predictor of cognitive decline during follow-up in prodromal AD is further investigated.
Methods:
A total of 406 MCI participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database were chosen and dichotomized into EMCI and LMCI groups according to the Second Edition (Logical Memory II) Wechsler Memory Scale. Multiple markers' data was collected, including age, sex, years of education, ApoE4 status, cerebrospinal fluid (CSF) biomarkers, standardized uptake values ratios (SUVR) means of florbetapir-PET-AV45, cognitive measures, and structural MRI. We chose 197 A+T+MCI participants (prodromal AD) with positive biomarkers of Aβ plaques (labeled "A") and fibrillar tau (labeled "T"). We diagnosed Aβ plaques positive by the SUVR means of florbetapir-PET-AV45 (cut-off >1.1) and fibrillar tau positive by CSF phosphorylated-tau at threonine 181 (p-tau) (cut-off >23 pg/mL). The differences of cognitive assessments and regions of interest (ROIs) defined on the MRI template between EMCI and LMCI were compared. Furthermore, the potential clinical utility of the MRI as the predictor of cognitive decline in prodromal AD was evaluated by investigating the relationship between baseline MRI markers and cognition decline at the follow-up period, through a linear regression model.
Results:
The LMCI participants had a significantly more amyloid burden and CSF levels of total t-tau than the EMCI participants. The LMCI participants scored a lower result than the EMCI group in the global cognition scales and subscales which included tests for memory, delayed recall memory, executive function, language, attention and visuospatial skills. The cognition levels declined faster in the LMCI participants during the 12- and 24-month follow-up. There were significant differences in ROIs on the structural MRI between the two groups, including a bilateral entorhinal, a bilateral hippocampus, a bilateral amygdala, a bilateral lateral ventricle and cingulate, a corpus callosum, and a left temporal. The thickness average of the left entorhinal, the left middle temporal, the left superior temporal, and the right isthmus cingulate was a main contributor to the decreased global cognition levels. The thickness average of the left superior temporal and bilateral entorhinal played a key role in the memory domain decline. The thickness average of the left middle temporal, and the right isthmus cingulate was significantly associated with an executive function decline.
Conclusions:
Based on the AT (N) system, surely, both the EMCI and LMCI diagnoses presented significant differences in multiple cognition domains. Signature ROIs from the structural MRI tests had correlated a cognitive decline, and could act as one potential predictive marker.
Insights
This study found that late mild cognitive impairment (LMCI) patients show greater Alzheimer's disease biomarker burden and faster cognitive decline than early MCI (EMCI) patients. Structural MRI markers in specific brain regions can predict cognitive decline in prodromal Alzheimer's disease.
Area of Science:
- Neuroscience
- Radiology
- Gerontology
Background:
- Mild cognitive impairment (MCI) due to Alzheimer's disease (AD) is extensively studied.
- Clinical and neuroimaging characteristics for prodromal AD (A+T+MCI) require further investigation.
- This study differentiates early MCI (EMCI) and late MCI (LMCI) using the AT(N) system.
Purpose of the Study:
- To evaluate cognitive and structural MRI differences between EMCI and LMCI.
- To explore the predictive value of structural MRI for cognitive decline in prodromal AD.
Main Methods:
- Analyzed 406 MCI participants from the ADNI database, categorizing them into EMCI and LMCI.
- Collected data on demographics, ApoE4 status, CSF biomarkers, amyloid PET, cognitive tests, and structural MRI.
- Focused on 197 A+T+MCI participants, defining positive Aβ plaques and tau biomarkers.
- Compared cognitive assessments and MRI regions of interest (ROIs) between EMCI and LMCI groups.
- Used linear regression to assess the relationship between baseline MRI markers and follow-up cognitive decline.
Main Results:
- LMCI participants exhibited higher amyloid burden and CSF t-tau levels than EMCI participants.
- LMCI participants showed significantly lower performance across global cognition and various subdomains (memory, executive function, etc.).
- Cognitive decline was more rapid in LMCI participants over 12 and 24 months.
- Significant structural MRI differences were observed in regions including the entorhinal cortex, hippocampus, amygdala, and ventricles.
- Specific MRI thickness measures in the entorhinal cortex, temporal lobe, and cingulate cortex correlated with global cognition, memory, and executive function decline.
Conclusions:
- EMCI and LMCI, defined by the AT(N) system, show distinct cognitive profiles.
- Signature ROIs identified via structural MRI correlate with cognitive decline.
- Structural MRI markers hold potential as predictive indicators for cognitive decline in prodromal AD.
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
Alzheimer Disease ll: Pathophysiology
Dementia l: Introduction

